LOGIN  |  REGISTER
Recursion
Viking Therapeutics

AirSculpt Technologies Announces Fourth Quarter 2022 Earnings Release Date and Conference Call

February 24, 2023 | Last Trade: US$5.35 0.14 -2.55

MIAMI BEACH, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will report fourth quarter 2022 financial results before market open on Friday, March 10, 2023, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.

The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13735890 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.elitebodysculpture.com. A replay of the webcast will be available for approximately 90 days.

About AirSculpt Technologies

AirSculpt Technologies (NASDAQ: AIRS) is an experienced, fast-growing national provider of body contouring procedures delivering a premium consumer experience under its brand, Elite Body Sculpture. At Elite Body Sculpture, we provide custom body contouring using our proprietary AirSculpt® method that removes unwanted fat in a minimally invasive procedure, producing dramatic results. It is our mission to generate the best results for our patients.

Investor Contact:

Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:

Stephanie Evans Greene
Chief Marketing Officer
AirSculpt Technologies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB